University of California, Los Angeles
This study aims to evaluate the effects of cardiotoxic cancer therapies on myocardial blood flow (MBF) and perfusion in a prospective sample of VA patients.
Up to 60 patients who will be newly initiating chemotherapy are going to be prospectively evaluated using PET myocardial perfusion imaging (MPI) for chemotherapy-induced cardiotoxicity by quantifying MBF and perfusion. Patients will be grouped into 3 categories: 1. Patients undergoing chemotherapy with anthracycline containing regimen. 2. Patients undergoing chemotherapy with VEGF inhibitor containing regimen. 3. Patients undergoing chemotherapy with immune check point inhibitor containing regimen. Patients will undergo PET MPI at 3 different time points: 1. Baseline PET MPI within 1 month…
Inclusion Criteria: * Veterans Affairs oncology patients who will be initiating chemotherapy * Ability to give consent Exclusion Criteria: * Prior chemotherapy * Prior coronary revascularization (percutaneous coronary intervention, coronary artery bypass grafting) * Anyone with previous invasive or CT (computed tomography) angiogram demonstrating any lesion ≥ 50% stenosis * Known cardiomyopathy defined as rest ejection fraction \< 50% * History of heart and/or another organ transplant * Pregnancy or breast-feeding status
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.